Savings Deadline Expires In:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
2-4 December 2024
Convention Centre DublinDublin, Ireland Jeremy SkillingtonCEO at Poolbeg PharmaSpeaker
Profile
Jeremy Skillington has a PhD in Biochemistry and spent 7 years at Genentech he executed over 40 licencing and other transactions. He has since been involved in a number of successful biotech start ups including inflazome which was acquired by Roche in a deal worth over USD410 million
Agenda Sessions
p38 MAPK inhibition - novel method to prevent CRS and enable safer administration of cell therapies
, 14:00View Session